Dosage
Occasionally, the use of novamine sulfone can cause allergic skin rashes or a drop in blood pressure. Rarely, spotty, pustular skin rashes or a deficiency of white blood cells (leukocytes) occur. Very rare side effects of novaminesulfone are During the application of novaminesulfone, a life-threatening blood formation disorder (so-called agranulocytosis) and a lack of blood platelets (thrombocytopenia) may occur.
Agranulocytosis begins unspecifically with a disturbance of the general condition and fever, later mucous membrane ulcers, skin necrosis and localized lymphomas occur. Especially if novamine sulfone is used for a longer period of time, the blood count should be checked regularly. If fever occurs when using Novaminsulfone, treatment should be stopped immediately and a doctor consulted.
However, the risk of life-threatening agranulocytosis when using novaminesulfone seems to be very low. In the recommended dose ranges, there is no known impairment of the concentration and reaction capacity, but impairment must be considered especially at higher doses, which is why the operation of machines, driving vehicles and other dangerous activities should be avoided.
- Painkiller Asthma
- Severe skin reactions (e.g. Stevens-Johnson syndrome, Lyell syndrome)
- Circulatory shock with clouding of consciousness
- Protein in urine
- Urinary retention
- Deterioration of renal function
- Urinary excretion deficiency
- Mental disorders such as anxiety, excitement, delusions, depression
When should novamine sulfone not be used?
Novamine sulfone should not be used if there is a hypersensitivity to the active ingredient metamizole or similar substances. The same applies if there is an intolerance to other painkillers (non-opioid painkillers, non-steroidal painkillers) in the form of allergic reactions. In cases of bone marrow function disorders, diseases of the haematopoietic system and certain liver function disorders (e.g. acute hepatic porphyria), the use of novamine sulfone is not indicated.
Special care should be taken when administering novamine sulfone in cases of allergic bronchial asthma, chronic urticaria, kidney and liver dysfunction, high fever, serious injury to coronary or cerebral vessels or after a cerebral infarction, and in people with low blood pressure or unstable circulation. In these cases novamine sulfone should only be prescribed after careful medical risk-benefit analysis. There may be drugs that interact with novaminesulfone treatment.
In principle, it is advisable to discuss any other drug already used with the treating physician before starting treatment with a new drug in order to rule out complications due to interactions. The use of novaminesulfone in children is stated differently for the individual dosage forms, depending on the manufacturer. Restrictions may be based on the age, but also on the body weight of the child.
The special warnings for each drug must therefore be observed. In general, novamine sulfone in tablet form is not approved for children under ten years of age. As suppositories, administration of 300 milligrams or more of Metamizole to children over four years of age and 1000 milligrams or more of Metamizole to adolescents over 15 years of age is approved.
Novaminsulfone is not approved for use in newborns and infants under three months of age or under five kilograms of body weight, as the tolerability of the active substance in this age group has not been sufficiently researched. Novaminsulfone is available in drop form for older children. Novaminsulfone solution may only be injected into the muscle tissue (intramuscularly) of a child older than three months; an injection into the vein (intravenously) is not indicated.
There have been few meaningful studies on the tolerability of novaminesulfone during pregnancy to date, as too few pregnant women have been treated with the active ingredient metamizole to be able to reliably assess tolerability. In principle, metamizole can reach the child through the placenta. In animal experiments, no damage to the unborn child has been observed, but it is recommended not to use novamine sulfone at all during the first and third trimesters of pregnancy.In the second third of pregnancy, the drug should only be administered after a strict medical risk-benefit assessment. The active ingredient metamizole inhibits the body’s own production of the tissue hormones prostaglandins, which can lead to an undersupply of blood to the unborn child and could cause complications at birth due to a disorder in blood clotting.
